CRBU
The corporate version of "we need to talk"
Caribou Biosciences says it’s kicking off a strategic review to maximize shareholder value. Translation: the board is opening the door to a possible merger, acquisition, business combination, or some other deal-shaped exit ramp.
CAR-T gets benched
The extra spicy part? The company also plans to halt its CAR-T programs. That’s not exactly the kind of sentence you want to read if you’re long the stock for its science. It suggests Caribou is pulling back from its current playbook and looking for a new path — or a buyer to help write one.
Why investors care
When a biotech starts talking about strategic alternatives, it usually means one of two things: the cash burn math got ugly, or the science isn’t translating into a clean commercial story. Either way, the market tends to treat it like a smoke alarm, which helps explain why the stock got dumped.
Big picture: this is less about a fresh growth chapter and more about a company trying to figure out what it wants to be when it grows up.